Key Highlights

  • The early indication of USD 1.24 on November 18, 2026 sits 8.17% under a calculated prior close of USD 1.35, a calculated drop of USD 0.11.
  • Cash stood at USD 9.5 million on September 30, 2026, up 15% from year-end 2025, which management expects to support planned preliminary operations into the second quarter of 2027.
  • Share count rose 339% to about 2.19 million by September 30, 2026 from 497,693 at year-end 2025, helped by roughly 1.69 million at-the-market shares that raised USD 8.2 million gross.
  • The exploratory placebo-adjusted forced vital capacity gain for GRI-0621 was 99 mL in a 35-patient, 12-week Phase 2a study, or 139 mL in the standard-of-care subset, and this is not proof of efficacy.

GRI Bio (NASDAQ:GRI) Slips in Early Trade With No Fresh Announcement

The early price for GRI Bio is USD 1.24 on November 18, 2026, a decline of 8.17% from the calculated prior close of USD 1.35 recorded on November 17. The USD move works out to negative USD 0.11. Applying the early price to roughly 2.19 million shares outstanding at September 30, 2026 gives a calculated Market Value near USD 2.72 million. Early-session Volume figures could not be found. That market value is an estimate built from the company's own share count, so it carries the usual limits for GRI Bio.

No Fresh Catalyst After the Third Quarter Update at GRI Bio

No announcement from GRI Bio dated November 18, 2026 was located. The newest update is the third quarter report, issued around November 13, 2026 and covering the period to September 30. Following a Type C meeting request, the company received written feedback from the FDA and plans another meeting on a proposed Phase 2b or adaptive Phase 2b/3 design, with the feedback itself and the budget undisclosed. As general context for GRI Bio, clinical-stage micro-caps tend to slip after updates that add no fresh figures.

Going-Concern Doubt, Dilution and Nano-Cap Exposure at GRI Bio

A question mark hangs over whether GRI Bio can keep operating as a going concern, a doubt the company itself raises. Cash of USD 9.5 million at September 30, 2026 sits against USD 6.6 million of operating outflow over nine months, and the balance is expected to support planned preliminary operations into the second quarter of 2027. The share count climbed to about 2.19 million from 497,693, with roughly 517,000 warrants outstanding, equal to about 24% of September 30 shares. The company says the market value of its listed securities is under USD 5 million, and a Nasdaq listing rule, stayed under review, could bring suspension and delisting proceedings if it takes effect. At a calculated market value near USD 2.72 million, the stock sits in nano-cap territory where Volatility runs high for GRI Bio.

Where Things Stand

Coverage does not connect the early decline in GRI Bio to a particular event. The indicated USD 1.24 sits 8.17% under a calculated USD 1.35 close, and the backdrop includes a reported 339% rise in share count, going-concern doubt and a pending listing question. Cash of USD 9.5 million and an exploratory trial readout are the reference points for investors. Pre-market moves can reverse at the open, and this is not Investment advice.